|
US6506798B1
(en)
|
1997-07-01 |
2003-01-14 |
Warner-Lambert Company |
4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
|
|
US6846799B1
(en)
|
1998-08-18 |
2005-01-25 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
US7354894B2
(en)
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
AU2180500A
(en)
*
|
1998-12-15 |
2000-07-03 |
Warner-Lambert Company |
Use of a mek inhibitor for preventing transplant rejection
|
|
WO2000040237A1
(en)
*
|
1999-01-07 |
2000-07-13 |
Warner-Lambert Company |
Antiviral method using mek inhibitors
|
|
ATE311363T1
(de)
|
1999-01-13 |
2005-12-15 |
Warner Lambert Co |
Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
|
|
DE69926914T2
(de)
|
1999-01-13 |
2006-06-29 |
Warner-Lambert Co. Llc |
1-heterozyklus-substituierte diarylaminen
|
|
IL144214A0
(en)
|
1999-01-13 |
2002-05-23 |
Warner Lambert Co |
Benzoheterocycles and their use as mek inhibitors
|
|
CA2348236A1
(en)
*
|
1999-01-13 |
2000-07-20 |
Stephen Douglas Barrett |
4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
|
|
CA2349832A1
(en)
|
1999-01-13 |
2000-07-20 |
Warner-Lambert Company |
Benzenesulfonamide derivatives and their use as mek inhibitors
|
|
PT1171418E
(pt)
*
|
1999-04-21 |
2005-02-28 |
Warner Lambert Co |
Metodo de preparacao de acidos 2-(n-fenilamino)benzoicos
|
|
US6686499B1
(en)
|
1999-04-21 |
2004-02-03 |
Warner-Lambert Company |
Method for making 2-(N-phenylamino)benzoic acids
|
|
GB9910579D0
(en)
*
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
GB9910577D0
(en)
*
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
KR20020012315A
(ko)
*
|
1999-07-16 |
2002-02-15 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
|
|
EP1339702A1
(en)
|
2000-03-15 |
2003-09-03 |
Warner-Lambert Company |
5-amide substituted diarylamines as mek inhibitors
|
|
MXPA02008103A
(es)
*
|
2000-03-15 |
2002-11-29 |
Warner Lambert Co |
Diarilaminas sustituidas con 5-amida como inhibidores mek.
|
|
DE10017480A1
(de)
*
|
2000-04-07 |
2001-10-11 |
Transmit Technologietransfer |
Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
|
|
JP3811775B2
(ja)
|
2000-07-19 |
2006-08-23 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
|
|
SK2072003A3
(en)
*
|
2000-08-25 |
2004-01-08 |
Warner Lambert Co |
Process for making N-aryl-anthranilic acids and their derivatives
|
|
EP1365796A2
(en)
|
2000-09-01 |
2003-12-03 |
Van Andel Institute |
Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
|
|
EP1337513A1
(en)
|
2000-11-02 |
2003-08-27 |
AstraZeneca AB |
4-substituted quinolines as antitumor agents
|
|
US7067532B2
(en)
|
2000-11-02 |
2006-06-27 |
Astrazeneca |
Substituted quinolines as antitumor agents
|
|
AU2002255852B2
(en)
*
|
2001-03-22 |
2006-11-09 |
Van Andel Research Institute |
Anthrax lethal factor inhibits tumor growth and angiogenesis
|
|
IL149462A0
(en)
*
|
2001-05-09 |
2002-11-10 |
Warner Lambert Co |
Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
|
|
DOP2003000556A
(es)
|
2002-01-23 |
2003-10-31 |
Warner Lambert Co |
Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
|
|
CA2473545A1
(en)
|
2002-01-23 |
2003-07-31 |
Warner-Lambert Company Llc |
N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
|
|
KR100984595B1
(ko)
|
2002-03-13 |
2010-09-30 |
어레이 바이오파마 인크. |
Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
|
|
US7235537B2
(en)
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
ES2331246T3
(es)
|
2003-07-24 |
2009-12-28 |
Warner-Lambert Company Llc |
Derivados de benzamidazol como inhibidores del mek.
|
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
TW200520745A
(en)
|
2003-09-19 |
2005-07-01 |
Chugai Pharmaceutical Co Ltd |
Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
|
|
NZ546011A
(en)
|
2003-10-21 |
2009-09-25 |
Warner Lambert Co |
Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
|
|
CN1905873A
(zh)
|
2003-11-19 |
2007-01-31 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
|
US7732616B2
(en)
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
US7517994B2
(en)
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
NZ590160A
(en)
|
2003-11-21 |
2012-07-27 |
Array Biopharma Inc |
AKT protein kinase inhibitors
|
|
UA89035C2
(ru)
|
2003-12-03 |
2009-12-25 |
Лео Фарма А/С |
Эфиры гидроксамовых кислот и их фармацевтическое применение
|
|
WO2005094830A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
TWI361066B
(en)
|
2004-07-26 |
2012-04-01 |
Chugai Pharmaceutical Co Ltd |
5-substituted-2-phenylamino benzamides as mek inhibitors
|
|
BRPI0514515A
(pt)
|
2004-08-17 |
2008-06-10 |
Hoffmann La Roche |
hidantoìnas substituìdas
|
|
TW200621766A
(en)
*
|
2004-09-17 |
2006-07-01 |
Hoffmann La Roche |
Substituted hydantoins
|
|
ZA200703912B
(en)
|
2004-10-20 |
2008-09-25 |
Serono Lab |
3-arylamino pyridine derivatives
|
|
ES2346998T3
(es)
|
2005-04-06 |
2010-10-22 |
Chugai Seiyaku Kabushiki Kaisha |
Procedimiento para la produccion de acido 2,3,4-trifluoro-5-(yodo o bromo)benzoico.
|
|
ES2405785T3
(es)
|
2005-05-18 |
2013-06-03 |
Array Biopharma Inc. |
Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
|
|
SI1934174T1
(sl)
|
2005-10-07 |
2011-08-31 |
Exelixis Inc |
Inhibitorji MEK in postopki za njihovo uporabo
|
|
US7612212B2
(en)
|
2006-02-22 |
2009-11-03 |
Hoffmann-La Roche Inc. |
Substituted hydantoins
|
|
JPWO2007132867A1
(ja)
|
2006-05-15 |
2009-09-24 |
杉本 芳一 |
癌の予防及び治療剤
|
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
CA2656566C
(en)
|
2006-07-06 |
2014-06-17 |
Array Biopharma Inc. |
Dihydrofuro pyrimidines as akt protein kinase inhibitors
|
|
ATE532789T1
(de)
|
2006-07-06 |
2011-11-15 |
Array Biopharma Inc |
Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
|
|
ATE523499T1
(de)
|
2006-07-06 |
2011-09-15 |
Array Biopharma Inc |
Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
|
|
EP1908751A1
(en)
*
|
2006-10-03 |
2008-04-09 |
EOS S.p.A. |
N-hydroxy benzamides with antitumour activity
|
|
BRPI0717374A2
(pt)
|
2006-10-23 |
2013-10-29 |
Takeda Pharmaceutical |
Inibidores de mapk/erk quinase
|
|
PL2101759T3
(pl)
|
2006-12-14 |
2019-05-31 |
Exelixis Inc |
Sposoby stosowania inhibitorów MEK
|
|
WO2008075741A1
(ja)
*
|
2006-12-20 |
2008-06-26 |
Keio University |
糖尿病治療剤及び予防剤
|
|
CN101918373B
(zh)
|
2007-07-05 |
2013-06-05 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
WO2009006567A2
(en)
|
2007-07-05 |
2009-01-08 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
ATE551336T1
(de)
|
2007-08-16 |
2012-04-15 |
Hoffmann La Roche |
Substituierte hydantoine
|
|
JP2011506533A
(ja)
|
2007-12-20 |
2011-03-03 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｍｅｋキナーゼ阻害剤としての置換ヒダントイン
|
|
EP2240455B1
(en)
|
2008-01-09 |
2012-12-26 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
|
|
ES2422733T3
(es)
|
2008-01-09 |
2013-09-13 |
Array Biopharma Inc |
Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
|
|
WO2009143224A2
(en)
|
2008-05-20 |
2009-11-26 |
Fox Chase Center Center |
Method for the treatment or prophylaxis of lymphangioleiomyomatosis (lam) and animal model for use in lam research
|
|
HRP20160044T1
(hr)
|
2008-08-04 |
2016-02-26 |
Merck Patent Gmbh |
Novi spojevi fenilamino izonikotinamida
|
|
RU2522444C2
(ru)
|
2008-08-27 |
2014-07-10 |
Лео Фарма А/С |
Производные пиридина в качестве ингибиторов рецепторов фактора роста эндотелия сосудов 2 подтипа (vegfr-2) и протеинтирозинкиназы
|
|
US8993630B2
(en)
|
2008-11-10 |
2015-03-31 |
Bayer Intellectual Property Gmbh |
Substituted sulphonamido phenoxybenzamides
|
|
WO2010068738A1
(en)
|
2008-12-10 |
2010-06-17 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
|
EP2491014A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted halophenoxybenzamide derivatives
|
|
US20120269803A1
(en)
|
2009-10-21 |
2012-10-25 |
Bayer Intellectual Property Gmbh |
Substituted benzosulphonamides
|
|
EP2491015A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
ES2576061T3
(es)
|
2010-02-25 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
|
|
BR112012022801B8
(pt)
|
2010-03-09 |
2019-10-29 |
Dana Farber Cancer Inst Inc |
método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
|
|
WO2012055953A1
(en)
|
2010-10-29 |
2012-05-03 |
Bayer Pharma Aktiengesellschaft |
Substituted phenoxypyridines
|
|
EP2655601A4
(en)
|
2010-12-22 |
2014-09-10 |
Fate Therapeutics Inc |
CELL CULTURAL PLATFORM FOR INDIVIDUAL CELL SIZING AND IMPROVED RESOLUTION OF IPSCS
|
|
RU2013148817A
(ru)
|
2011-04-01 |
2015-05-10 |
Дженентек, Инк. |
Комбинации соединений-ингибиторов акт и мек и способы их применения
|
|
WO2012135781A1
(en)
|
2011-04-01 |
2012-10-04 |
Genentech, Inc. |
Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
EP2714037B1
(en)
|
2011-05-25 |
2016-07-13 |
Université Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
|
CN103204825B
(zh)
|
2012-01-17 |
2015-03-04 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
|
|
US20150141470A1
(en)
|
2012-05-08 |
2015-05-21 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
KR102204520B1
(ko)
|
2012-10-12 |
2021-01-20 |
엑셀리시스, 인코포레이티드 |
암의 치료에 사용하기 위한 화합물의 신규 제조 방법
|
|
EP3043822A1
(en)
|
2013-09-11 |
2016-07-20 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Compositions for preparing cardiomyocytes
|
|
AU2015206603B9
(en)
|
2014-01-14 |
2019-07-18 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
|
|
CA2941004A1
(en)
|
2014-03-04 |
2015-09-11 |
Peter Flynn |
Improved reprogramming methods and cell culture platforms
|
|
US10023879B2
(en)
|
2014-06-04 |
2018-07-17 |
Fate Therapeutics, Inc. |
Minimal volume reprogramming of mononuclear cells
|
|
CN105384754B
(zh)
*
|
2014-09-02 |
2018-04-20 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
CA2963091A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
|
WO2016123100A1
(en)
|
2015-01-26 |
2016-08-04 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
|
CN117737124A
(zh)
|
2015-10-16 |
2024-03-22 |
菲特治疗公司 |
用于诱导和维护基态多能性的平台
|
|
SG11201803145RA
(en)
|
2015-11-04 |
2018-05-30 |
Fate Therapeutics Inc |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
KR20250141836A
(ko)
|
2015-11-04 |
2025-09-29 |
페이트 세러퓨틱스, 인코포레이티드 |
만능 세포의 유전자 조작
|
|
SG11201805186VA
(en)
|
2016-01-20 |
2018-07-30 |
Fate Therapeutics Inc |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
JP7653759B2
(ja)
|
2016-01-20 |
2025-03-31 |
フェイト セラピューティクス，インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
EP3490975B1
(en)
*
|
2016-07-28 |
2021-05-05 |
The Johns Hopkins University |
O-substituted hydroxamic acids
|
|
EP3548049A4
(en)
|
2016-12-05 |
2020-07-22 |
Fate Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
|
|
CN107556201B
(zh)
*
|
2017-09-08 |
2020-10-27 |
山西智创药研科技有限公司 |
一种制备间氨基苯酚的工艺方法
|
|
WO2020106305A1
(en)
*
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Thienyl-aniline compounds for treatment of dermal disorders
|
|
CA3120351A1
(en)
*
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
|
EA202192575A1
(ru)
|
2019-03-21 |
2022-01-14 |
Онксео |
Соединения dbait в сочетании с ингибиторами киназ для лечения рака
|
|
CN114761006A
(zh)
|
2019-11-08 |
2022-07-15 |
Inserm(法国国家健康医学研究院) |
对激酶抑制剂产生耐药性的癌症的治疗方法
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|